

ImprimisRx NJ is recalling the following product to the patient level.

**Product:** Timolol-Latanoprost (0.5/0.005) % (5ml Ophthalmic topical drops in LDPE bottles)

**Description:** Ophthalmic Solution

**Lot Numbers:** Lot 06272022@3 and Lot 08302022@1

Batch Number	Date Made	Beyond Use Date (Expires on)	Shipped from
06272022@3	06/27/2022	11/24/2022	07/07/2022 to 09/08/2022
08302022@1	08/30/2022	01/27/2023	09/14/2022 to 10/31/2022

This recall has been initiated due to sub-potency. The batches contain less than 90% of the labeled amount of latanoprost.

ImprimisRx NJ is notifying its patients by phone and mail and is arranging for the return of the affected lots.

We will refund any medication the patients will be returning. Please complete and return the enclosed "Return Response Form" along with any product you are returning, using the return label provided to ImprimisRx NJ, Attn: Suja Alum at 1705 Route 46 W, Suite 4, Ledgewood, NJ 07852. You may also fax this completed form to (855) 405-4669.

Patients with questions regarding this recall can contact ImprimisRx NJ at 844-446-6979 Monday through Friday, 9am to 5pm EST or at [Imprimisrxnj@imprimisrx.com](mailto:Imprimisrxnj@imprimisrx.com). Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these preparations.

Adverse reactions experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by Fax.

- **Online:** [https://fda.gov/safety/medwatch-fda-safety-information-and-adverse event-reporting-program](https://fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program)
- **Regular Mail:** Reporting can be done through our online reporting portal or by downloading, completing, and then submitting FDA Form 3500 (health professional) or 3500B (consumer/patient) to Mail to the address on the pre-addressed form.
- **To fax report:** 1-800-FDA (332)-0178

This recall is being made with the knowledge of the Food and Drug Administration.